

Att. Docket No. REG 900A  
USSN 10/055,842 filed January 23, 2002  
Response to February 25, 2002 Notice to File  
Missing Parts of Nonprovisional Application

IN THE SPECIFICATION:

Please replace the paragraph starting on page 11, line 6, with the following:

**Figure 1A-1G.** ephrin-B2 is highly expressed at sites of secondary angiogenesis in the embryo, as well as at sites of normal and pathological angiogenesis in the adult. **Figure 1A-1G** are from ephrin-B2/LacZ mice.

**Figure 1A-1B:** ephrin-B2/LacZ is strongly expressed during physiological maturing ovarian follicles (**Figure 1A**) (arrows indicate capillaries) and in the neovasculature (arrowheads) of the corpus luteum after ovulation (**Figure 1B**). **Figure 1C-1D:** ephrin-B2/LacZ is strongly expressed in the neovasculature of a subcutaneously grown tumor (Lewis Lung Carcinoma). At high magnification LacZ staining is absent in veins (indicated by closed arrowheads), but is found in longitudinally oriented endothelial cells (open arrowheads in **Figure 1D**), also seen in a higher power view (inset). **Figure 1E-1G:** ephrin-B2 expression in a subset of tumor endothelial cells. (**Figure 1E**) Beta-galactosidase immunostaining marks a proportion of the endothelial cells labeled by PECAM (**Figure 1F**). Corresponding regions between **Figure 1E** and **Figure 1F** indicated by white arrowheads). **Figure 1G:** In a section of tumor dual-labeled for beta-galactosidase and smooth muscle actin (SMA), ephrin-B2 activity is found in endothelial cells (green arrowheads), but not in pericytes (red arrowheads).